Published on
October 13, 2025
- 15:00 GMT
Aveta Biomics to Present at the Upcoming 2025 ESMO Congress
ESMO data illuminate APG-157’s immune-modulating mechanism in Head and Neck Cancer ahead of the upcoming Phase 3 trial and its broad therapeutic potential BEDFORD, MA, UNITED STATES, October 13, 2025 /EINPresswire.com/ -- Aveta Biomics, a clinical-stage …
Distribution channels:
Banking, Finance & Investment Industry, Business & Economy
...
